A number of other brokerages also recently issued reports on BRKR. Zacks Investment Research downgraded Bruker from a hold rating to a sell rating and set a $46.00 price target on the stock. in a research report on Tuesday, October 15th. ValuEngine upgraded Bruker from a sell rating to a hold rating in a research report on Friday, November 1st. Bank of America upgraded Bruker from a neutral rating to a buy rating and set a $52.00 price target on the stock in a research report on Thursday, September 26th. Stifel Nicolaus began coverage on Bruker in a research report on Thursday, November 14th. They set a hold rating and a $53.00 price target on the stock. Finally, Needham & Company LLC set a $58.00 price target on Bruker and gave the stock a buy rating in a research report on Friday, September 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $50.91.
BRKR stock traded down $0.71 during trading on Friday, hitting $48.87. 330,803 shares of the company traded hands, compared to its average volume of 541,142. The stock’s 50-day simple moving average is $48.80 and its 200 day simple moving average is $45.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.23 and a quick ratio of 1.32. The company has a market cap of $7.53 billion, a PE ratio of 34.91, a P/E/G ratio of 2.43 and a beta of 1.43. Bruker has a 1 year low of $26.10 and a 1 year high of $52.23.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, October 31st. The medical research company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.05. The company had revenue of $521.10 million for the quarter, compared to the consensus estimate of $493.52 million. Bruker had a return on equity of 28.02% and a net margin of 10.20%. Bruker’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.37 earnings per share. Research analysts expect that Bruker will post 1.62 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 20th. Shareholders of record on Monday, December 2nd will be issued a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.33%. Bruker’s payout ratio is currently 11.43%.
In other Bruker news, Director Marc A. Kastner sold 3,203 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $47.39, for a total transaction of $151,790.17. Following the completion of the transaction, the director now owns 7,608 shares of the company’s stock, valued at $360,543.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Mark Munch sold 47,203 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $42.87, for a total value of $2,023,592.61. Following the transaction, the vice president now directly owns 96,063 shares of the company’s stock, valued at approximately $4,118,220.81. The disclosure for this sale can be found here. 26.50% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Virginia Retirement Systems ET AL acquired a new stake in shares of Bruker in the second quarter valued at approximately $340,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Bruker in the second quarter valued at approximately $519,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Bruker by 8.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,566 shares of the medical research company’s stock valued at $328,000 after purchasing an additional 492 shares during the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Bruker in the second quarter valued at approximately $698,000. Finally, Aperio Group LLC increased its holdings in shares of Bruker by 10.1% in the second quarter. Aperio Group LLC now owns 23,388 shares of the medical research company’s stock valued at $1,169,000 after purchasing an additional 2,144 shares during the last quarter. 68.92% of the stock is owned by institutional investors and hedge funds.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: How does equity income fit into an investing strategy?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.